Giant cell tumor of bone
Conditions
Interventions
Experimental group:ICG-based-NIR fluorescence imaging assisted intralesional curettage
Sponsors
Musculoskeletal tumor center, Peking University People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1). Aged 18-65. 2) Biopsy confirmed giant cell tumor of bone. 3) The lesions located in the limbs. 4) This operation is the initial treatment. 5) Denosumab and diphosphonates are not used before surgery. 6) Planned operation is intralesional curettage and filling bone defects with bone cement. 7) Preoperative bone scan and thin layer (layer thickness =3.5mm) chest CT plain scan confirmed that the lesion is a single occurrence without metastasis. 8) Subjects fully understand the benefits and risks of this experiment and are still willing to participate and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1). Known allergy to iodine contrast, indocyanine green or bone cement. 2). Severe hepatic and renal insufficiency. 3). During pregnancy or lactation. 4). Have other malignant tumors and are receiving related medical treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Accuracy of ICG fluorescence predicting residual tumor lesions;Correlation between ICG fluorescence intensity and pathological results of residual tumor lesions; | — |
Countries
China
Contacts
Public ContactTang Xiaodong
Peking University People's Hospital
Outcome results
None listed